175 related articles for article (PubMed ID: 37522998)
1. Diagnostic value of alkaline phosphatase and bone-specific alkaline phosphatase for metastases in breast cancer: a systematic review and meta-analysis.
Jiang C; Hu F; Li J; Gao G; Guo X
Breast Cancer Res Treat; 2023 Nov; 202(2):233-244. PubMed ID: 37522998
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of alkaline phosphatase and bone-specific alkaline phosphatase in breast cancer: A systematic review and meta-analysis.
Jiang C; Hu F; Xia X; Guo X
Int J Biol Markers; 2023 Mar; 38(1):25-36. PubMed ID: 36775971
[TBL] [Abstract][Full Text] [Related]
3. Biochemical markers for assessment of bone metastases in patients with breast cancer.
Hou MF; Tsai LY; Tsai SM; Huang CJ; Huang YS; Hsieh JS; Chan HM; Wang JY; Chuang CH; Chen FM; Huang TJ
Kaohsiung J Med Sci; 1999 Aug; 15(8):452-60. PubMed ID: 10518361
[TBL] [Abstract][Full Text] [Related]
4. Serum bone-specific alkaline phosphatase as a biomarker for osseous metastases in patients with malignant carcinomas: a systematic review and meta-analysis.
Du WX; Duan SF; Chen JJ; Huang JF; Yin LM; Tong PJ
J Cancer Res Ther; 2014 Nov; 10 Suppl():C140-3. PubMed ID: 25450272
[TBL] [Abstract][Full Text] [Related]
5. Serum calcium, alkaline phosphotase and hemoglobin as risk factors for bone metastases in bladder cancer.
Huang P; Lan M; Peng AF; Yu QF; Chen WZ; Liu ZL; Liu JM; Huang SH
PLoS One; 2017; 12(9):e0183835. PubMed ID: 28902911
[TBL] [Abstract][Full Text] [Related]
6. Serum bone alkaline phosphatase and CA 549 in breast cancer with bone metastases.
Cooper EH; Forbes MA; Hancock AK; Parker D; Laurence V
Biomed Pharmacother; 1992; 46(1):31-6. PubMed ID: 1421033
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.
Pectasides D; Farmakis D; Nikolaou M; Kanakis I; Kostopoulou V; Papaconstantinou I; Karamanos NK; Economopoulos T; Raptis SA
J Pharm Biomed Anal; 2005 Feb; 37(1):171-6. PubMed ID: 15664758
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of simultaneous determination of bone alkaline phosphatase mass concentration in serum and urinary excretion of pyridinium cross-links for detection of bone metastases.
Withold W; Georgescu G; Khakzad H; Vosberg H; Mueller-Gaertner HW; Reinauer H
Clin Biochem; 1995 Oct; 28(5):511-9. PubMed ID: 8582050
[TBL] [Abstract][Full Text] [Related]
9. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of SPECT/CT bone imaging combined with two serum examinations in patients with bone metastases from pulmonary cancer.
Zhou Y; Li C; Jiang S; Niu F; Cui F; Zhao Y; Wei D; Ma H; Li Y
Clin Transl Oncol; 2024 Jan; 26(1):147-154. PubMed ID: 37269491
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
[TBL] [Abstract][Full Text] [Related]
12. Expressiveness of Bone Markers in Breast Cancer with Bone Metastases.
Zulauf N; Brüggmann D; Groneberg D; Oremek GM
Oncology; 2019; 97(4):236-244. PubMed ID: 31412345
[TBL] [Abstract][Full Text] [Related]
13. Clinical Application of the Ratio of Serum Bone Isoform to Total Alkaline Phosphatase in General Practice.
Yokota Y; Nishimura Y; Ando A; Hanayama Y; Hasegawa K; Hagiya H; Ogawa H; Obika M; Ueda K; Otsuka F
Acta Med Okayama; 2020 Dec; 74(6):467-474. PubMed ID: 33361866
[TBL] [Abstract][Full Text] [Related]
14. Plasma acid and alkaline phosphatase in patients with breast cancer.
Nguyen M; Bonneterre J; Hecquet B; Desoize B; Demaille A
Anticancer Res; 1991; 11(2):831-3. PubMed ID: 2064338
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostic value of bone metabolic markers ICTP and BAP in lung cancer patients with bone metastases].
Xin Y; Han B; Lou J; Wu J; Niu Y
Zhongguo Fei Ai Za Zhi; 2010 Oct; 13(10):947-53. PubMed ID: 20959067
[TBL] [Abstract][Full Text] [Related]
16. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma.
Díaz-Martín MA; Traba ML; De La Piedra C; Guerrero R; Méndez-Dávila C; De La Peña EG
Scand J Clin Lab Invest; 1999 Apr; 59(2):125-32. PubMed ID: 10353326
[TBL] [Abstract][Full Text] [Related]
17. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
[TBL] [Abstract][Full Text] [Related]
18. Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report.
Shimozuma K; Sonoo H; Fukunaga M; Ichihara K; Aoyama T; Tanaka K
Jpn J Clin Oncol; 1999 Jan; 29(1):16-22. PubMed ID: 10073146
[TBL] [Abstract][Full Text] [Related]
19. Skeletal alkaline phosphatase as a serum marker of bone metastases in the follow-up of patients with breast cancer.
Reale MG; Santini D; Marchei GG; Manna A; Del Nero A; Bianco V; Marchei P; Frati L
Int J Biol Markers; 1995; 10(1):42-6. PubMed ID: 7629426
[TBL] [Abstract][Full Text] [Related]
20. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
Kanakis I; Nikolaou M; Pectasides D; Kiamouris C; Karamanos NK
J Pharm Biomed Anal; 2004 Mar; 34(4):827-32. PubMed ID: 15019061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
